NASDAQ:FUSNFusion Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Fusion Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $13.13 -0.50 (-3.67 %) (As of 08/5/2020 04:00 PM ET) Add Compare Share Today's Range$13.13Now: $13.13▼$13.9850-Day Range N/A52-Week Range$12.19Now: $13.13▼$19.00Volume47,124 shsAverage Volume287,264 shsMarket Capitalization$547.05 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsInsider TradesInstitutional OwnershipHeadlinesSocial Media Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingFusion Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $24.33, Fusion Pharmaceuticals has a potential upside of 85.3% from its current price of $13.13.Amount of Analyst CoverageFusion Pharmaceuticals has only been the subject of 4 research reports in the past 90 days. Previous Next 0.0 Community Rank Outperform VotesFusion Pharmaceuticals has received 4 “outperform” votes. (Add your “outperform” vote.)Underperform VotesFusion Pharmaceuticals has received 0 “underperform” votes. (Add your “underperform” vote.)MarketBeat's community ratings are surveys of what our community members think about Fusion Pharmaceuticals and other stocks. Vote “Outperform” if you believe FUSN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe FUSN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldFusion Pharmaceuticals does not currently pay a dividend.Dividend GrowthFusion Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Fusion Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $12,325,000.00 in company stock and sold $0.00 in company stock. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Fusion Pharmaceuticals are expected to grow in the coming year, from ($1.37) to ($0.25) per share. Previous Next Analyst Opinion: 3.5Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.43 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:FUSN Previous Symbol CUSIPN/A CIKN/A Webfusionpharma.com Phone289-799-0891Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees37 Outstanding Shares41,664,000Market Cap$547.05 million Next Earnings DateN/A OptionableNot Optionable $13.13 -0.50 (-3.67 %) (As of 08/5/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive FUSN News and Ratings via Email Sign-up to receive the latest news and ratings for FUSN and its competitors with MarketBeat's FREE daily newsletter. Fusion Pharmaceuticals (NASDAQ:FUSN) Frequently Asked Questions Do Wall Street analysts recommend investors buy shares of Fusion Pharmaceuticals? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fusion Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Fusion Pharmaceuticals. What price target have analysts set for FUSN? 4 brokers have issued 12-month price objectives for Fusion Pharmaceuticals' shares. Their forecasts range from $23.00 to $25.00. On average, they expect Fusion Pharmaceuticals' share price to reach $24.33 in the next twelve months. This suggests a possible upside of 85.3% from the stock's current price. View analysts' price targets for Fusion Pharmaceuticals. Has Fusion Pharmaceuticals been receiving favorable news coverage? Press coverage about FUSN stock has trended neutral recently, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Fusion Pharmaceuticals earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news about Fusion Pharmaceuticals. Who are some of Fusion Pharmaceuticals' key competitors? Some companies that are related to Fusion Pharmaceuticals include Immunovant (IMVT), SpringWorks Therapeutics (SWTX), Mesoblast (MESO), Editas Medicine (EDIT), Legend Biotech (PCVX), Sangamo Therapeutics (SGMO), Adverum Biotechnologies (ADVM), NanoString Technologies (NSTG), Bill.com (RVMD), Forma Therapeutics (FMTX), Coherus Biosciences (CHRS), Regenxbio (RGNX), Cortexyme (CRTX), Alector (ALEC) and Adaptimmune Therapeutics (ADAP). View all competitors. When did Fusion Pharmaceuticals IPO? (FUSN) raised $126 million in an IPO on Friday, June 26th 2020. The company issued 8,400,000 shares at $14.00-$16.00 per share. Morgan Stanley, Jefferies and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. What is Fusion Pharmaceuticals' stock symbol? Fusion Pharmaceuticals trades on the NASDAQ under the ticker symbol "FUSN." When did the company's quiet period expire? Fusion Pharmaceuticals' quiet period expired on Wednesday, August 5th. Fusion Pharmaceuticals had issued 12,500,000 shares in its IPO on June 26th. The total size of the offering was $212,500,000 based on an initial share price of $17.00. During the company's quiet period, insiders and underwriters that worked on the IPO were prevented from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company. Who are Fusion Pharmaceuticals' major shareholders? Fusion Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include UBS Group AG (0.01%). View institutional ownership trends for Fusion Pharmaceuticals. Which major investors are buying Fusion Pharmaceuticals stock? FUSN stock was purchased by a variety of institutional investors in the last quarter, including UBS Group AG. View insider buying and selling activity for Fusion Pharmaceuticals. How do I buy shares of Fusion Pharmaceuticals? Shares of FUSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Fusion Pharmaceuticals' stock price today? One share of FUSN stock can currently be purchased for approximately $13.13. How big of a company is Fusion Pharmaceuticals? Fusion Pharmaceuticals has a market capitalization of $547.05 million. Fusion Pharmaceuticals employs 37 workers across the globe. What is Fusion Pharmaceuticals' official website? The official website for Fusion Pharmaceuticals is fusionpharma.com. How can I contact Fusion Pharmaceuticals? Fusion Pharmaceuticals' mailing address is 270 LONGWOOD ROAD SOUTH, HAMILTON A6, L8P 0A6. The company can be reached via phone at 289-799-0891 or via email at [email protected] This page was last updated on 8/5/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
